Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brilanestrant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 19/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brilanestrant SCHEMBL29423494 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL766996 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL29356277 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL31540920 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL766995 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL767351 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL17502345 | 1.00 | ESR1 (1.00) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL767216 | 0.99 | ESR1 (0.98) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL767215 | 0.99 | ESR1 (0.98) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 | |
| Brilanestrant SCHEMBL767218 | 0.99 | ESR1 (0.98) | ESR1CYP2C9CYP2C19NR3C1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | claimed |
| EP-3180316-A1 | CRYSTALLINE FORMS OF AN ESTROGEN RECEPTOR MODULATOR | F. Hoffmann-La Roche AG (CH) | 2017-06-21 | — | — | EP | claimed |
| WO-2016023847-A1 | CRYSTALLINE FORMS OF AN ESTROGEN RECEPTOR MODULATOR | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-18 | — | — | WO | claimed |
| EP-2735562-B1 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2015-03-11 | — | — | EP | claimed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-2828243-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-3180316-A1 | CRYSTALLINE FORMS OF AN ESTROGEN RECEPTOR MODULATOR | F. Hoffmann-La Roche AG (CH) | 2017-06-21 | — | — | EP | disclosed |
| EP-3116496-A1 | METHODS AND COMPOSITIONS FOR MODULATING ESTROGEN RECEPTOR MUTANTS | F. Hoffmann-La Roche AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-9499538-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| EP-3089747-A1 | ESTROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR POSITIVE BREAST CANCER | F. Hoffmann-La Roche AG (CH) | 2016-11-09 | — | — | EP | disclosed |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2616445-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8455534-B2 | Estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130012561-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8299112-B2 | Estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | ESR1 4/4885CYP2C9 1600/4885CYP2C19 581/4885 |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | ESR1 4/4885CYP2C9 1609/4885CYP2C19 584/4885 |
| US-20130012561-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | ESR1 4/4885CYP2C9 1609/4885CYP2C19 584/4885 |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | ESR1 4/4885CYP2C9 1609/4885CYP2C19 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.